How Stiripentol Enhances GABA Activity
Stiripentol primarily boosts GABAergic neurotransmission by acting as a positive allosteric modulator of GABAA receptors. It binds to a distinct site on the receptor—separate from the benzodiazepine or barbiturate sites—increasing the frequency of chloride channel opening when GABA is present. This leads to greater chloride influx, hyperpolarizing neurons and reducing seizure excitability.[1][2]
Does It Directly Activate Receptors?
Stiripentol shows minimal intrinsic activity on GABAA receptors without GABA. Unlike barbiturates, it does not open channels on its own at therapeutic doses, making its effects GABA-dependent and reducing risks of excessive sedation.[1][3]
Effects on GABA Levels and Metabolism
Beyond modulation, stiripentol inhibits GABA transaminase (GABA-T), the enzyme that breaks down GABA into succinic semialdehyde. This raises extracellular GABA concentrations in the brain, prolonging its availability at synapses and amplifying GABAA receptor stimulation indirectly.[2][4]
Impact on Receptor Subtypes
It preferentially enhances activity at GABAA receptors containing α3 subunits, common in cortical and hippocampal regions prone to epileptic activity. This selectivity contributes to its efficacy in Dravet syndrome, where it complements clobazam by potentiating its metabolite norclobazam.[3][5]
Clinical Relevance in Epilepsy
These mechanisms—modulation plus GABA preservation—explain stiripentol's add-on role in refractory epilepsies. Studies show 50-70% seizure reduction in Dravet patients, tied to sustained GABA enhancement without tolerance buildup.[4][5]
Comparisons to Other GABA Modulators
| Mechanism | Stiripentol | Benzodiazepines | Barbiturates | Vigabatrin |
|-----------|-------------|-----------------|--------------|------------|
| Allosteric modulation | Yes (GABA-dependent) | Yes (α/γ subunit) | Yes (high-affinity) | No |
| GABA-T inhibition | Yes | No | No | No (GAT-1 inhibition) |
| Direct activation | Minimal | Minimal | Yes | No |
| Tolerance risk | Low | High | High | Low |
Stiripentol's dual action sets it apart, offering broader GABA support than single-target drugs.[1][2]
Sources
[1]: DrugPatentWatch.com - Stiripentol Patent Insights
[2]: Neuropsychiatr Dis Treat. 2017;13:1907-1914. PubMed
[3]: Epilepsia. 2007;48 Suppl 5:30-32. PubMed
[4]: CNS Drugs. 2019;33(7):647-662. PubMed
[5]: Lancet Neurol. 2018;17(11):996-1005. PubMed